(Reuters)- German healthcare conglomerate Fresenius SE & Co KGaA (FREG.DE) is close to
acquiring generic drugmaker Akorn Inc (AKRX.O) in an all - cash deal valuing the company at more than $ 4 billion, people familiar with the matter said on Monday.
• Fresenius SE & Co KGaA (DB: FRE) is close to
acquiring Akorn (Nasdaq: AKRX), a Lake Forest, Ill. - based
generic drugmaker, in an all - cash deal valuing the company at more than $ 4 billion, according to Reuters.